Innocoll prices IPO at $9, below the range

Comment

Shutterstock photo

Innocoll, which develops absorbable collagen drugs to treat pain, foot infections and adhesions, raised $59 million by offering 6.5 million ADSs (upsized from 5.4 million) at $9, below the range of $13 to $15. Insiders were expected to purchase $27 million (46% of the deal). Innocoll plans to list on the NASDAQ under the symbol INNL. Innocoll initially filed confidentially on 3/26/2014. Piper Jaffray and Stifel acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com